BioSpace News Archive

Montreal-based ELNA Medical, a leading Quebec provider of healthcare services, announced that it has completed the acquisition of Medicentres Canada, the largest chain of corporately owned medical clinics in the country.

Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, and other leaders in global biopharmaceutical investment

HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) is pleased to announce the appointment of Rose Marie Gage to its Board of Directors

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results. Preliminary Fourth Quarter and Full-Year 2020 Revenue Results Fourth quarter 2020 revenue is expected to be in a range of $387 to $389 million, representing a decrease of 2.1% to 1.6% on a reported basis and a decrease of 1.9% to 1.4% on an

PureTech Health plc is pleased to note that its Founded Entity, Follica, announced the appointment of two veteran biotech executives to its Board of Directors.

Follica Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other related conditions, announced the appointment of two veteran biotech executives to its Board of Directors.

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021 , at 8:00 a.m. CST to review second quarter 2021 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 2, 2

Significant investment from General Atlantic and The Vistria Group positions CareMetx for continued growth in supporting patient access to innovative therapies

A broad coalition of health and technology leaders today announced the creation of the Vaccination Credential Initiative (VCI), committed to empowering individuals with digital access to their vaccination records based on open, interoperable standards.

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in an oral symposium and three poster presentations during the 2021 American Professional Society of ADHD and Related Disorders (APSARD) Vi